Please use this identifier to cite or link to this item:
https://olympias.lib.uoi.gr/jspui/handle/123456789/21272Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Bassioukas, K. | en |
| dc.contributor.author | Zioga, A. | en |
| dc.contributor.author | Hantschke, M. | en |
| dc.contributor.author | Klouvas, G. | en |
| dc.contributor.author | Hatzis, J. | en |
| dc.date.accessioned | 2015-11-24T19:14:14Z | - |
| dc.date.available | 2015-11-24T19:14:14Z | - |
| dc.identifier.issn | 1167-1122 | - |
| dc.identifier.uri | https://olympias.lib.uoi.gr/jspui/handle/123456789/21272 | - |
| dc.rights | Default Licence | - |
| dc.subject | Aged | en |
| dc.subject | Biopsy, Needle | en |
| dc.subject | Dose-Response Relationship, Drug | en |
| dc.subject | Drug Administration Schedule | en |
| dc.subject | Female | en |
| dc.subject | Follow-Up Studies | en |
| dc.subject | Hemorrhage/drug therapy/pathology | en |
| dc.subject | Humans | en |
| dc.subject | Immunohistochemistry | en |
| dc.subject | Injections, Subcutaneous | en |
| dc.subject | Interferon-alpha/*administration & dosage | en |
| dc.subject | Recombinant Proteins | en |
| dc.subject | Risk Assessment | en |
| dc.subject | Sarcoma, Kaposi/*drug therapy/*pathology | en |
| dc.subject | Skin Neoplasms/*drug therapy/*pathology | en |
| dc.subject | Treatment Outcome | en |
| dc.title | Hemorrhagic Kaposi sarcoma. Successful treatment with IFN-alpha | en |
| heal.type | journalArticle | - |
| heal.type.en | Journal article | en |
| heal.type.el | Άρθρο Περιοδικού | el |
| heal.identifier.secondary | http://www.ncbi.nlm.nih.gov/pubmed/14965794 | - |
| heal.language | en | - |
| heal.access | campus | - |
| heal.recordProvider | Πανεπιστήμιο Ιωαννίνων. Σχολή Επιστημών Υγείας. Τμήμα Ιατρικής | el |
| heal.publicationDate | 2004 | - |
| heal.abstract | A 76-year-old woman with atypical hemorrhagic Kaposi sarcoma is presented. The patient was treated with recombinant interferon alpha-2b (3,000,000 IU) subcutaneously, three times weekly for 6 months and twice weekly as maintenance dose for 14 months with excellent response and no recurrence after a 7 years of follow-up. | en |
| heal.journalName | Eur J Dermatol | en |
| heal.journalType | peer-reviewed | - |
| heal.fullTextAvailability | TRUE | - |
| Appears in Collections: | Άρθρα σε επιστημονικά περιοδικά ( Ανοικτά) - ΙΑΤ | |
Files in This Item:
There are no files associated with this item.
This item is licensed under a Creative Commons License
